Analyst Price Targets — STRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 14, 2025 1:19 pm | — | Piper Sandler | $2.00 | $0.81 | TheFly | Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler |
| October 11, 2024 7:01 am | Tazeen Ahmad | Bank of America Securities | $12.00 | $3.61 | StreetInsider | BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO) |
| October 11, 2024 6:36 am | Andrew Fein | H.C. Wainwright | $12.00 | $3.61 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO) |
| August 16, 2024 6:58 am | Asthika Goonewardene | Truist Financial | $15.00 | $4.21 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $15 at Truist Securities |
| May 14, 2024 4:12 pm | James Shin | Deutsche Bank | $10.00 | $4.34 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank |
| May 14, 2024 8:25 am | David Nierengarten | Wedbush | $8.00 | $4.23 | StreetInsider | Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO) |
| April 3, 2024 2:01 pm | Jay Olson | Oppenheimer | $10.00 | $5.09 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO) |
| April 3, 2024 6:48 am | Edward Tenthoff | Piper Sandler | $11.00 | $5.09 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler |
| April 2, 2024 4:12 pm | Asthika Goonewardene | Truist Financial | $18.00 | $5.09 | StreetInsider | Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities |
| January 13, 2023 8:27 am | — | Truist Financial | $25.00 | $8.14 | Benzinga | Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25 |
Latest News for STRO
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be…
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STRO.
U.S. House Trading
No House trades found for STRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.